Stock Traders Buy High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of some unusual options trading on Tuesday. Stock traders acquired 15,360 call options on the stock. This is an increase of 44% compared to the average volume of 10,636 call options.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $9.25.

Insider Activity

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $6.31, for a total transaction of $37,860.00. Following the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,288,380.78. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,341 shares of company stock valued at $393,490 in the last ninety days. 15.75% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. ARK Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 16.4% during the 3rd quarter. ARK Investment Management LLC now owns 32,769,186 shares of the company’s stock valued at $215,949,000 after buying an additional 4,626,268 shares in the last quarter. State Street Corp raised its position in Recursion Pharmaceuticals by 47.1% during the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the period. Lingotto Investment Management LLP lifted its stake in shares of Recursion Pharmaceuticals by 69.0% in the 2nd quarter. Lingotto Investment Management LLP now owns 3,675,077 shares of the company’s stock valued at $27,563,000 after purchasing an additional 1,500,000 shares during the last quarter. Ghisallo Capital Management LLC purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $8,250,000. Finally, Perceptive Advisors LLC bought a new position in shares of Recursion Pharmaceuticals during the 2nd quarter valued at approximately $5,769,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Price Performance

RXRX traded down $0.35 on Tuesday, hitting $7.60. 11,610,648 shares of the company’s stock traded hands, compared to its average volume of 16,851,018. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $15.74. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.97 billion, a price-to-earnings ratio of -4.97 and a beta of 0.85. The company’s 50 day simple moving average is $6.89 and its 200-day simple moving average is $7.03.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The company had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s revenue was up 147.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.43) EPS. As a group, research analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.